Rhumbline Advisers raised its stake in shares of DaVita HealthCare Partners Inc. (NYSE:DVA) by 4.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 321,155 shares of the company’s stock after buying an additional 13,471 shares during the quarter. Rhumbline Advisers owned about 0.17% of DaVita HealthCare Partners worth $19,073,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its holdings in shares of DaVita HealthCare Partners by 1,987.3% during the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock worth $2,448,000 after purchasing an additional 39,746 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DaVita HealthCare Partners in the third quarter valued at $154,000. FDx Advisors Inc. boosted its holdings in DaVita HealthCare Partners by 28.6% in the third quarter. FDx Advisors Inc. now owns 46,836 shares of the company’s stock valued at $2,782,000 after acquiring an additional 10,427 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in DaVita HealthCare Partners by 14.7% in the third quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock valued at $26,390,000 after acquiring an additional 56,988 shares during the last quarter. Finally, Speece Thorson Capital Group Inc. boosted its holdings in DaVita HealthCare Partners by 14.5% in the third quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock valued at $19,075,000 after acquiring an additional 40,667 shares during the last quarter. Hedge funds and other institutional investors own 85.32% of the company’s stock.
Shares of DaVita HealthCare Partners Inc. (NYSE:DVA) traded up $8.27 during trading on Wednesday, reaching $69.20. The company had a trading volume of 9,753,886 shares, compared to its average volume of 1,639,774. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40. The company has a market capitalization of $11,719.12, a price-to-earnings ratio of 17.69, a P/E/G ratio of 12.48 and a beta of 0.97. DaVita HealthCare Partners Inc. has a 1 year low of $52.51 and a 1 year high of $70.16.
DaVita HealthCare Partners (NYSE:DVA) last issued its earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.13). The company had revenue of $3.92 billion during the quarter, compared to analyst estimates of $3.91 billion. DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.31%. The business’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.95 earnings per share. equities analysts anticipate that DaVita HealthCare Partners Inc. will post 3.42 EPS for the current year.
DaVita HealthCare Partners declared that its Board of Directors has initiated a stock buyback program on Tuesday, October 10th that allows the company to buyback $1.50 billion in shares. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.
A number of research analysts recently weighed in on the company. KeyCorp reiterated a “hold” rating on shares of DaVita HealthCare Partners in a report on Wednesday. J P Morgan Chase & Co lowered DaVita HealthCare Partners from a “neutral” rating to an “underweight” rating in a research report on Monday, October 9th. Wolfe Research raised DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a research report on Monday, October 23rd. Royal Bank Of Canada cut their price objective on DaVita HealthCare Partners from $64.00 to $60.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 8th. Finally, Robert W. Baird reissued a “hold” rating and issued a $63.00 price objective on shares of DaVita HealthCare Partners in a research report on Friday, November 10th. Four research analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. DaVita HealthCare Partners currently has a consensus rating of “Hold” and an average price target of $63.00.
DaVita HealthCare Partners Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.